NCT04469127View on ClinicalTrials.gov

A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients.

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 30, 2024

Primary Completion Date

August 30, 2025

Study Completion Date

August 30, 2025

Conditions
Breast Cancer Stage IV
Interventions
DRUG

Lutetium-177-DOTAGA-IAC

Study participants be administered therapeutic doses of Lutetium-177-DOTAGA-IAC up to three treatments spaced 4 weeks apart.

Trial Locations (2)

2193

CM Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg

160 012

Postgraduate Institute of Medical and Research, Chandigarh

All Listed Sponsors
collaborator

University of Witwatersrand, South Africa

OTHER

collaborator

Postgraduate Institute of Medical and Research

UNKNOWN

lead

Advanced Imaging Projects, LLC

INDUSTRY

NCT04469127 - A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients. | Biotech Hunter | Biotech Hunter